These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32658841)

  • 1. Development of a hyperimmune equine serum therapy for COVID-19 in Argentina.
    Zylberman V; Sanguineti S; Pontoriero AV; Higa SV; Cerutti ML; Morrone Seijo SM; Pardo R; Muñoz L; Acuña Intrieri ME; Alzogaray VA; Avaro MM; Benedetti E; Berguer PM; Bocanera L; Bukata L; Bustelo MS; Campos AM; Colonna M; Correa E; Cragnaz L; Dattero ME; Dellafiore M; Foscaldi S; González JV; Guerra LL; Klinke S; Labanda MS; Lauché C; López JC; Martínez AM; Otero LH; Peyric EH; Ponziani PF; Ramondino R; Rinaldi J; Rodríguez S; Russo JE; Russo ML; Saavedra SL; Seigelchifer M; Sosa S; Vilariño C; López Biscayart P; Corley E; Spatz L; Baumeister EG; Goldbaum FA
    Medicina (B Aires); 2020; 80 Suppl 3():1-6. PubMed ID: 32658841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.
    Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Lorenzi JCC; Finkin S; Hägglöf T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ
    Cell; 2020 Aug; 182(4):828-842.e16. PubMed ID: 32645326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and development of equine hyperimmune globulin F(ab')2 against severe acute respiratory syndrome coronavirus.
    Lu JH; Guo ZM; Han WY; Wang GL; Zhang DM; Wang YF; Sun SY; Yang QH; Zheng HY; Wong BL; Zhong NS
    Acta Pharmacol Sin; 2005 Dec; 26(12):1479-84. PubMed ID: 16297347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin fragment F(ab')
    Pan X; Zhou P; Fan T; Wu Y; Zhang J; Shi X; Shang W; Fang L; Jiang X; Shi J; Sun Y; Zhao S; Gong R; Chen Z; Xiao G
    Antiviral Res; 2020 Oct; 182():104868. PubMed ID: 32659292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays.
    DomBourian MG; Annen K; Huey L; Andersen G; Merkel PA; Jung S; Dominguez SR; Knight V
    J Immunol Methods; 2020 Nov; 486():112837. PubMed ID: 32828791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Convalescent serum lines up as first-choice treatment for coronavirus.
    Sheridan C
    Nat Biotechnol; 2020 Jun; 38(6):655-658. PubMed ID: 32358594
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.
    Yi Z; Ling Y; Zhang X; Chen J; Hu K; Wang Y; Song W; Ying T; Zhang R; Lu H; Yuan Z
    Emerg Microbes Infect; 2020 Dec; 9(1):1988-1996. PubMed ID: 32844713
    [No Abstract]   [Full Text] [Related]  

  • 8. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.
    Nie J; Li Q; Wu J; Zhao C; Hao H; Liu H; Zhang L; Nie L; Qin H; Wang M; Lu Q; Li X; Sun Q; Liu J; Fan C; Huang W; Xu M; Wang Y
    Emerg Microbes Infect; 2020 Dec; 9(1):680-686. PubMed ID: 32207377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Passive antibody therapy in COVID-19.
    Abraham J
    Nat Rev Immunol; 2020 Jul; 20(7):401-403. PubMed ID: 32533109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19.
    Franchini M; Del Fante C; Klersy C; Glingani C; Percivalle E; Baldanti F; Perotti C
    Semin Thromb Hemost; 2020 Oct; 46(7):804-806. PubMed ID: 32512588
    [No Abstract]   [Full Text] [Related]  

  • 14. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
    Hansen J; Baum A; Pascal KE; Russo V; Giordano S; Wloga E; Fulton BO; Yan Y; Koon K; Patel K; Chung KM; Hermann A; Ullman E; Cruz J; Rafique A; Huang T; Fairhurst J; Libertiny C; Malbec M; Lee WY; Welsh R; Farr G; Pennington S; Deshpande D; Cheng J; Watty A; Bouffard P; Babb R; Levenkova N; Chen C; Zhang B; Romero Hernandez A; Saotome K; Zhou Y; Franklin M; Sivapalasingam S; Lye DC; Weston S; Logue J; Haupt R; Frieman M; Chen G; Olson W; Murphy AJ; Stahl N; Yancopoulos GD; Kyratsous CA
    Science; 2020 Aug; 369(6506):1010-1014. PubMed ID: 32540901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
    Lindholm PF; Ramsey G; Kwaan HC
    Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.
    Lu Y; Wang Y; Zhang Z; Huang J; Yao M; Huang G; Ge Y; Zhang P; Huang H; Wang Y; Li H; Wang W
    J Immunol Res; 2020; 2020():9465398. PubMed ID: 33134398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
    Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z
    Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.